Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies

Core Insights - Liminatus Pharma, Inc. has initiated a strategic internal review to explore the potential formation of a dedicated digital asset investment vehicle [1][2] - The prospective subsidiary aims to diversify the company's long-term treasury strategy and will operate independently from its core clinical pipeline [2] - If approved, the company anticipates targeting up to $500 million in potential capital formation through various financing tools [3] Company Overview - Liminatus Pharma is a preclinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies [6] - The company is advancing a pipeline of novel therapies that target cancer antigens and tumor-specific immune responses [6] - Liminatus is committed to responsible innovation in capital strategy to support its long-term scientific and operational objectives [6] Current Status - No capital has been raised or committed, and no agreements or partnerships have been established at this stage [4] - The internal review is subject to final Board approval, regulatory compliance, and prevailing market conditions [4][5] - The company is working with legal, financial, and regulatory advisors to determine the optimal structure and compliance framework for the proposed initiative [5]